Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications

Breast Cancer Research and Treatment

Volumn 164, Issue 2, 2017, Pages 263-284

  Cintolo Gonzalez, Jessica A ^a   Braun, Danielle ^b,c   Blackford, Amanda L ^d   Mazzola, Emanuele ^c   Acar, Ahmet ^a   Plichta, Jennifer K ^e   Griffin, Molly ^a   Hughes, Kevin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Breast Cancer Screening; Risk assessment; Risk Models

Indexed keywords

BREAST CANCER; BREAST CANCER RISK ASSESSMENT TOOL; BREAST CANCER SURVEILLANCE CONSORTIUM MODEL; BREAST CARCINOGENESIS; BREAST DENSITY; CANCER RISK; CANCER SCREENING; DISEASE ASSESSMENT; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FAMILY HISTORY; GERMLINE MUTATION; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HORMONE RESPONSE; HUMAN; MAMMOGRAPHY; MANCHESTER SCORING SYSTEM; MASTECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; STATISTICAL MODEL;

BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS;

EID: 85018694314     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-017-4247-z     Document Type: Review

References (120)

1. Fitzmaurice, C., et al., Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol, 2016
2. Euhus DM et al (2002) Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J 8(1):23–27
3. Evans DG, Howell A (2007) Breast cancer risk-assessment models. Breast Cancer Res 9(5):213
4. Steyerberg EW et al (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21(1):128–138
5. Anothaisintawee T et al (2012) Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat 133(1):1–10
6. Gail MH et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886
7. Costantino JP et al (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91(18):1541–1548
8. Spiegelman D et al (1994) Validation of the Gail et al model for predicting individual breast cancer risk. J Natl Cancer Inst 86(8):600–607
9. Rockhill B et al (2001) Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358–366
10. http://www.cancer.gov/bcrisktool
11. Banegas MP et al (2012) Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat 132(1):347–353
12. Min JW et al (2014) Validation of risk assessment models for predicting the incidence of breast cancer in korean women. J Breast Cancer 17(3):226–235
13. Chay WY et al (2012) Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res 14(1):R19
14. Adams-Campbell LL et al (2007) Diagnostic accuracy of the Gail model in the Black Women’s Health Study. Breast J 13(4):332–336
15. Fisher B, Costantino JP (1999) RESPONSE: re: tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 91(21):1891A–1892A
16. Vogel VG et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741
17. Fisher B et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662
18. Saslow D et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89
19. http://dceg.cancer.gov/tools/risk-assessment/care. Available from: ht
20. Gail MH et al (2007) Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 99(23):1782–1792
21. Study TW (1998) Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials. 19(1):61–109
22. Adams-Campbell LL et al (2009) Breast cancer risk assessments comparing Gail and CARE models in African-American women. Breast J 15(Suppl 1):S72–S75
23. Banegas MP et al (2013) The risk of developing invasive breast cancer in Hispanic women: a look across Hispanic subgroups. Cancer 119(7):1373–1380
24. Banegas, M.P., John, E.M., Slattery, M., Gomez, S.L., Yu, M., LaCroix, A., Pee D., Gail, M.H., A09: Projecting individualized absolute invasive breast cancer risk in Hispanic women., in Eighth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserverd2015: Atlanta, GA
25. Boyd NF et al (1998) Mammographic densities and breast cancer risk. Breast Dis 10(3–4):113–126
26. Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629
27. del Carmen MG et al (2007) Mammographic breast density and race. AJR Am J Roentgenol 188(4):1147–1150
28. Baglietto L et al (2014) Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. Am J Epidemiol 179(4):475–483
29. Warwick J et al (2014) Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res 16(5):451
30. Chen J et al (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226
31. Benichou J et al (2003) Secular stability and reliability of measurements of the percentage of dense tissue on mammograms. Cancer Detect Prev 27(4):266–274
32. Barlow WE et al (2006) Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98(17):1204–1214
33. Arrospide A et al (2013) An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain. BMC Cancer 13:587
34. Tice JA et al (2013) Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst 105(14):1043–1049
35. Tice JA et al (2008) Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 148(5):337–347
36. Tice JA et al (2005) Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 94(2):115–122
37. Vachon CM et al (2015) The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. 107(5):dju397
38. https://tools.bcsc-scc.org/BC5yearRisk/intro.htm. December 9, 2016]
39. Bodian CA, Perzin KH, Lattes R (1996) Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 78(5):1024–1034
40. Singletary SE (2003) Rating the risk factors for breast cancer. Ann Surg 237(4):474–482
41. Bodian CA (1983) Risk of carcinoma of the breast after various benign breast diseases: use of standardized mortality/morbidity ratios for follow-up data [dissertation]. Columbia University, New York
42. https://www4.utsouthwestern.edu/breasthealth/cagene
43. Pankratz VS et al (2015) Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol 33(8):923–929
44. Hartmann LC et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237
45. Gail MH, Pfeiffer RM (2015) Is the Benign Breast Disease Breast Cancer Model Well Calibrated? J Clin Oncol 33(25):2829–2830
46. Rosner B, Colditz GA (1996) Nurses’ health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88(6):359–364
47. Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152(10):950–964
48. Rosner BA et al (2013) Validation of Rosner–Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Res Treat 142(1):187–202
49. Tworoger SS et al (2014) Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol 32(28):3111–3117
50. Petracci E et al (2011) Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst 103(13):1037–1048
51. Franceschi S et al (1996) Intake of macronutrients and risk of breast cancer. Lancet 347(9012):1351–1356
52. Mezzetti M et al (1998) Population attributable risk for breast cancer: diet, nutrition, and physical exercise. J Natl Cancer Inst 90(5):389–394
53. Calza S et al (2003) EPIC-Italy cohorts and multipurpose national surveys. A comparison of some socio-demographic and life-style characteristics. Tumori 89(6):615–623
54. Masala G et al (2003) The Florence city sample: dietary and life-style habits of a representative sample of adult residents. a comparison with the EPIC-Florence volunteers. Tumori 89(6):636–645
55. Parmigiani G et al (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147(7):441–450
56. Claus EB, Risch N, Thompson WD (1993) The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 28(2):115–120
57. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73(3):643–651
58. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48(2):232–242
59. McTiernan A et al (2001) Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomark Prev 10(4):333–338
60. van Asperen CJ et al (2004) Risk estimation for healthy women from breast cancer families: new insights and new strategies. Cancer Epidemiol Biomark Prev 13(1):87–93
61. Armstrong K, Eisen A, Weber B (2000) Assessing the risk of breast cancer. N Engl J Med 342(8):564–571
62. Euhus DM (2001) Understanding mathematical models for breast cancer risk assessment and counseling. Breast J 7(4):224–232
63. Shattuck-Eidens D et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278(15):1242–1250
64. Vahteristo P et al (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84(5):704–708
65. Frank TS et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417–2425
66. Frank TS et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490
67. Panchal SM et al (2008) Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet 9:116
68. Barcenas CH et al (2006) Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354–360
69. Bodmer D et al (2006) Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models. Br J Cancer 95(6):757–762
70. Kang E et al (2012) Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients. Breast Cancer Res Treat 134(3):1189–1197
71. Kwong A et al (2012) Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. World J Surg 36(4):702–713
72. Rao NY et al (2009) Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. Breast Cancer Res Treat 116(3):563–570
73. Weitzel JN et al (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297(23):2587–2595
74. http://www.myriadpro.com/hereditary-cancer-testing/hereditary-breast-and-ovarian-cancer-hboc-syndrome/brca-risk-calculator/
75. http://www.myriadpro.com/hereditary-cancer-testing/hereditary-breast-and-ovarian-cancer-hboc-syndrome/prevalence-tables/
76. Couch FJ et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415
77. http://apps.afcri.upenn.edu/itacc/penn2/. University of Pennsylvania Abramson Cancer Center. The Penn II BRCA1and BRCA2 Mutation Risk Evaluation Model. Philadelphia, PA. [cited 2016 July 2016]
78. Lindor NM et al (2010) Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer 9(4):495–502
79. Kang HH et al (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95(7):914–920
80. Amir E et al (2010) Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 102(10):680–691
81. Evans DG et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480
82. Evans DG et al (2005) Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 42(7):e39
83. Evans DG et al (2009) Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 46(12):811–817
84. Antoniou AC et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425–431
85. Kast K et al (2014) Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. Int J Cancer 135(10):2352–2361
86. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing-table-1-ontario-family-history-assessment-tool. Final recommendation statement: BRCA-related Cancer: Risk Assessment, Genetic Counseling, Genetic Testing. [cited 2016 December 9, 2016]
87. Gilpin CA, Carson N, Hunter AG (2000) A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 58(4):299–308
88. Bellcross CA et al (2009) Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 11(11):783–789
89. Berg AO, Allan JD, Calonge N, Frame PS (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143(5):355–361
90. Berrino F, Bellati C (1999) COS, case-only-study on breast cancer before the age of 40. Announcement of a new study on gene-environment interaction in breast cancer. Epidemiol Prev 23(1):57–59
91. Roudgari H, Miedzybrodzka ZH, Haites NE (2008) Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models. Fam Cancer 7(3):199–212
92. Berrino J et al (2015) Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Fam Cancer 14(1):117–128
93. Berry DA et al (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89(3):227–238
94. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158
95. Mazzola E et al (2015) Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO. Cancer Inform 14(Suppl 2):147–157
96. Biswas S et al (2013) Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571–579
97. http://bayesmendel.dfci.harvard.edu/risk/
98. http://hughesriskapps.com/
99. http://www.progenygenetics.com/clinical/risk
100. Antoniou AC et al (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86(1):76–83
101. Antoniou AC et al (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580–1590
102. Antoniou AC et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(8):1457–1466
103. Lee AJ et al (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110(2):535–545
104. Lee AJ et al (2016) Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med 18(12):1190–1198
105. Antoniou AC et al (2006) BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8(1):R3
106. Schneegans SM et al (2012) Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families. Fam Cancer 11(2):181–188
107. Fischer C et al (2013) Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 50(6):360–367
108. http://ccge.medschl.cam.ac.uk/boadicea/
109. Jonker MA et al (2003) Modeling familial clustered breast cancer using published data. Cancer Epidemiol Biomark Prev 12(12):1479–1485
110. Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130
111. Quante AS et al (2012) Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 14(6):R144
112. Amir E et al (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40(11):807–814
113. Fasching PA et al (2007) Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. Eur J Cancer Prev 16(3):216–224
114. Boughey JC et al (2010) Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol 28(22):3591–3596
115. Subramanian J et al (2015) An integrated breast cancer risk assessment and management model based on fuzzy cognitive maps. Comput Methods Programs Biomed 118(3):280–297
116. Brentnall AR et al (2015) Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Res 17(1):147
117. http://www.ems-trials.org/riskevaluator
118. Hollingsworth AB, Stough RG (2014) An alternative approach to selecting patients for high-risk screening with breast MRI. Breast J 20(2):192–197
119. Nelson HD et al (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160(4):255–266
120. Visvanathan K et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(23):2942–2962